New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sitemap


Articles from 2019 In November


Omega-3 supplements don't increase prostate cancer risk, study shows

Omega-3 supplements don't increase prostate cancer risk, study shows

Two new studies from the Intermountain Healthcare Heart Institute demonstrated that omega-3 supplements will help reduce patients' risk of heart attack, stroke, heart failure or death—but not increase their chances of developing prostate cancer.

Their findings were 2019 presented on Nov. 17 at the American Heart Association Scientific Sessions in Philadelphia, Pennsylvania.

Approximately 1 in 9 men are diagnosed with prostate cancer, according to the American Cancer Association, with 60% of cases showing up in men who are 65 years old or older.

A 2013 analysis published in the Journal of the National Cancer Institute suggested that men with the highest levels of polyunsaturated fatty acids in their blood were at increased risk of prostate cancer.

Viet T. Le, a researcher and physician assistant at the Intermountain Healthcare Heart InstituteViet T. Le, a researcher and physician assistant at the Intermountain Healthcare Heart Institute, said researchers undertook this study in light of those findings.

“If I’m recommending omega-3 for my patients to save their hearts, I want to make sure I’m not putting them at risk for prostate cancer,” Le said. “Our study found no evidence of a link between the two.”

For their study, the Intermountain research team identified 87 patients who were part of the Intermountain INSPIRE Registry and had developed prostate cancer. These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are two common omega-3 fatty acids.

When compared to a matched control group of 149 men, the researchers found that higher omega-3 levels were not linked with elevated prostate cancer risk.

Le earned his master's of physician assistant studies at the University of Utah School of Medicine in 2004. He's been employed at Intermountain Healthcare as a cardiology and research physician's assistant since October 2012 and an assistant professor at Rocky Mountain University of Health Professions since June 2015.

Omega-3s effective in reducing risk of cardiac diseases

For the second study presented at the 2019 American Heart Association Scientific Sessions, Intermountain researchers looked at 894 patients undergoing coronary angiography, a test that shows how blood flows through the arteries in the heart.

These patients had no prior history of heart attack or coronary artery disease; however, upon their first angiogram, about 40% of those patients had severe disease and about 10% had three-vessel disease, Le said.

Researchers also measured patients’ plasma levels of omega-3 metabolites, including DHA and EPA. They then followed the patients to see who suffered a subsequent heart attack, stroke or heart failure, or who died.

Researchers found that patients with higher rates of omega-3 metabolites had lower risk of those adverse effects regardless of whether they had severe disease or not on their initial angiogram.

“This study is important because we looked at how omega-3 helps patients who have already developed disease, and its effects on survival—both in getting to the first angiography to be diagnosed (versus having a heart attack or worse before even knowing they have heart disease) and thereafter,” Le said.

“While a seeming association between higher plasma omega-3 levels and the findings of severe heart disease upon initial angiogram might raise alarms that omega-3 isn’t beneficial, they did live to see a doctor and get diagnosed,” Le added. “And we saw a link between higher levels of omega-3 and their survival rate thereafter.”

Other members of the research team include: Kirk U. Knowlton, M.D., director of cardiovascular research at Intermountain Heart Institute; Raymond O. McCubrey, MS; Stacey Knight, who holds a doctorate in biomedical informatics with a focus on genetic epidemiology, oversees the Intermountain Geneaology Registry for use in family-based genetic research; Jeramie Watrous, holds a PhD in biological chemistry from the University of California, San Diego, and is an assistant professor of medicine there; Mohit Jain, M.D., holds a doctorate in pharmacology from Boston University and is an associate professor at UCSD; and more.

This research was sponsored by the Intermountain Research and Medical Foundation and the Dell Loy Hansen Foundation, Inc.

Source: Intermountain Heatlhcare

FDA ups the ante in its war against CBD

Getty CBD oil tincture with gloved hands

The FDA released a new consumer guidance document on cannabidiol (CBD) that “raises significant concerns” among the hemp CBD industry because the FDA undersells its benefits and overstates the risks, according to CBD backers.

The agency released the guidance in conjunction with warning letters and an explicit position that CBD is a drug only, and illegal for use in foods, beverages, supplements and animal products.

“This is a significant, concerted and highly orchestrated effort by FDA to put the brakes on the CBD market,” said Loren Israelsen, president of the United Natural Products Alliance and a veteran of FDA and congressional affairs. “The viewpoints and perspectives of the respective interests in this issue are becoming clearer as the anticipated struggle to determine the status of CBD and the other cannabinoids has begun.”

The FDA’s letter contained common elements with past pronouncements, but also goes further in its attempts to stop the CBD market, despite the 2018 Farm Bill that legalized hemp CBD—but gives a say to FDA to regulate the market as it sees fit.

Suffice it to say that it was not congressional intent for the FDA to declare that the entire affair should be declared illegal. Still, the FDA is standing firm in its belief that the CBD genie should be put back in the bottle.

“The FDA is concerned that people may mistakenly believe that trying CBD ‘can’t hurt,’” wrote the FDA in its guidance document

“The agency wants to be clear that we have seen only limited data about CBD’s safety and these data point to real risks that need to be considered. As part of the drug review and approval process for the prescription drug containing CBD, it was determined that the risks are outweighed by the benefits of the approved drug for the particular population for which it was intended. Consumers should be aware of the potential risks associated with using CBD products. Some of these can occur without your awareness.”

Among the health risks the agency said it has seen are liver injury, drug interactions and male reproductive toxicity in laboratory animals. Other effects the FDA claimed CBD possesses include drowsiness, diarrhea and changes in mood.

The FDA approved a CBD isolate for use in two child-onset epileptic seizure conditions for those ages 2 and up.

The Epidiolex maximum recommended maintenance dose is 20 milligrams per kilogram of body weight, or about 1,400 mg/day for a 150-pound person.

Typical dietary supplements of hemp CBD range from 5 to 25 mg—far below the amount prescribed in the pharmaceutical CBD, and usually found as a full spectrum hemp oil extract and not in isolate form.

It is for reasons like this that the hemp CBD industry is up in arms about the FDA’s proclamations.

“CV Sciences is disappointed that FDA’s consumer update … used an inappropriately alarmist tone,” said Duffy MacKay, senior vice president of scientific and regulatory affairs at CV Sciences, makers of PlusCBD Oil. “CV Sciences is concerned that FDA is creating a narrative that questions the safety of CBD to try to address the significant number of fly-by-night companies entering the CBD industry.”

The US Hemp Roundtable, which lobbies governments from the state to federal level, also was concerned with the FDA’s interpretation and pronouncements. The organization said in an email that the FDA “severely overstates the health risks of hemp-derived CBD and that ignores much of the scientific evidence of CBD’s safety, in particular at dosage levels typically found in foods and dietary supplements.”

The FDA consumer guidance document was released the same day that the agency sent out a new raft of warning letters—its first in nearly four years

Don't make drug-disease claims! 

All 15 companies cited by the FDA were dinged as being unapproved new drugs—that is, they were making drug-disease claims and not dietary supplement-style structure/function claims.

“The common thread in these warning letters,” said Asa Waldstein, chair of the cannabis committee for the American Herbal Products Association, “is egregious health claims on websites including product reviews, but also with a clearer focus on social media.”

Waldstein is heading a public meeting in Boulder, Colorado, on Dec. 17, “Ethical CBD Marketing: How to avoid FDA, FTC and class-action trouble.” 

One brand that received a warning letter, KOI CBD, based in California, made claims that CBD can benefit pain, inflammation, schizophrenia, breast cancer, diabetes, opioid addiction, PTSD, fibromyalgia, multiple sclerosis and Crohn’s disease. The company also offered its CBD products in animal feed.

Noli Oil, from Texas, received a warning letter because it claimed CBD was good for cancer, psoriasis, ADD, ADHD, alcoholism, autism, bipolar disorder, depression, diabetes, epilepsy, fibromyalgia, irritable bowel syndrome, migraines, mood disorders, multiple sclerosis, Parkinson’s, psychosis, PTSD and schizophrenia. These claims were made both overtly, via testimonials as well as social media accounts.

Bella Rose Labs, based in New York, also made illegal drug-disease claims, and also had no clear directions for use. The company’s gummies were also deemed by the FDA to be an unapproved food additive.

“The agency has yet to target companies that are not making claims,” said Israelsen, “but it has expanded its concerns over common claims, such as stress, anxiety and pain.”

At least one of the warning letters mentions combination products, CBD with curcumin, and it cites the cancer claim tied to the curcumin.

The agency is also requesting health practitioners to submit adverse events reports to the FDA.

The FDA indicated that it will provice an update on its progress “in the coming weeks.”

“We anticipate,” said Israelsen, “that additional warning letters will be issued.”

The FDA sent its consumer guidance document to all members of Congress—clearly an attempt at swaying any potential legislation Congress might take up in the absence of any near-term action by the FDA.

[email protected]: Soy farming starves honeybees | Mexico bans glyphosate

5@5: Soy farming starves honeybees | Mexico bans glyphosate

How conventional soy farming starves honeybees

While all commodity crop production is detrimental to honeybee populations, conventional soy farming in particular is depleting the quantity and variety of foods that honeybees typically rely on in the U.S. Researchers found that honeybee colonies near conventional soy farms are turning to their food stores for sustenance as early as August, making them far less likely to survive the winter. Read more at New Food Economy

Mexico bars shipment of glyphosate pesticide

This week Mexico's environment department barred a 1000-ton shipment from entering the country because of "health and environmental concerns." Meanwhile, glyphosate remains in use stateside even as the amount of successful lawsuits from people who claim the herbicide causes cancer continues to grow. Read more at Reuters

Is lab-grown turkey in your Thanksgiving future?

A poultry expert familiar with lab-grown meat of all varieties has come to the conclusion that turkey cells are "the ideal platform for making cultured meat" and that there are fewer quality control problems with growing cells from poultry than there are with red meat. But will consumers ever forgo traditional turkey for the holidays? That remains to be seen. Read more at Civil Eats

Concerns after Waitrose reintroduces plastic packaging at 'green' Botley Road, Oxford, branch

Shoppers at Waitrose are alarmed after discovering the supermarket is once again offering plastic bags in place of paper ones. They also noted that the supermarket has not yet made good on its promise to reduce plastic packaging in the produce section. Read more at Bicester Advertiser

How pro-meat Twitter scrambled the rollout of the Planetary Health Diet

After the planet-friendly, plant-heavy Planetary Health Diet was unveiled by Harvard-backed institution EAT-Lancet, meat-eaters were "especially vocal" about the drawbacks of the diet and the study. And this had an unforseen and potent effect on how many people ended up skeptical about the diet's validity and ability to be implemented on a large scale. Read more at Quartz

Can a 'transparency badge' make CBD more transparent?

Matthew Kind of CannaInsider

If one thing is clear about the exploding CBD market is that it lacks clarity, but Matthew Kind thinks a "transparency badge" can clear up at least some of the confusion. All companies need to do is show they have third-party testing results and then post them publicly to qualify, but the CannaInsider podcast host thinks that’s the kind of shorthand consumers want.

We talked to him about the Transparency Badge and the state of the CBD market. Read more about developments in the hemp and CBD market in Nutrition Business Journal’s Hemp & CBD Guide 2.0.

NBJ's proprietary research shows consumers are confused about almost every aspect of CBD. How much of an answer will they find in the transparency badge?

Matthew Kind: What the transparency badge does is creates a common baseline. What I'm trying to do here is eliminate the things that can hurt you, take the bad stuff out of the picture, so we can focus on what makes a CBD stand out. So, you can compare on full spectrum. You can compare on lab testing, sourcing and then maybe the cannabinoid profile. But the certification badge is a quality benchmark here where all the bad stuff most people would worry about has been taken care of. And there's a public document that can certify that.

What are the most common questions you hear from consumers?

MK: What’s the difference between the types of oils and how much should I take? Obviously, I'm not a doctor, but with most botanicals or drugs, most people are really about taking too much but I think in the world of CBD, there's more of a risk of taking too little, where you don't feel the effects of it.

Where do you point people to get answers?

MK: We interview a lot of people on our podcast. That helps. There’s the Hemp Roundtable. The place we point them to probably the most is third-party lab testing. There are a good number of the CBD companies that do provide third-party lab testing if you're asking for it. I want to make it so that everybody provides that all the time, and then makes it public on the website.

When you are using CBD, what do you look for in a brand?

MK: The first thing that goes through my mind is ‘where was this made?’ If it was made in another country that's not necessarily bad, but a lot of times it comes from China or maybe someplace in Eastern Europe and it could have been used as a soil remediator. That’s the real risk because then hemp acts like a sponge and soaks whatever is in the soil up. Then I’d ask if it’s full spectrum or isolated? Is it third-party lab tested? And then, what's the cannabinoid profile like?

You’ve said the vast majority of CBD companies are testing for quality and potency. A lot of people would call that a huge overstatement. What do you base that on?

MK: Let's just look at the top market leaders. Let's look at like a Bluebird Botanicals or a Medterra or anybody you want to say is in the top tier and we could find some sort of third-party lab testing. We may not be able to get all of it, but we can find some third-party lab testing or request it.

There was controversy at Natural Products Expo East with the Center for Food Safety’s Hemp CBD Scorecard. Is the hemp CBD industry ready to police itself without falling into mudslinging?

MK:The best way is to highlight the people that are really trying to follow the best practices. Let the rest of the industry come to them. Meet on the high road.

How do CBD companies earn the badge and what does it cost?

MK: The cost is nothing, it's free, and it's at cannainsider.com/CBD-transparency. It leads them through a series of questions. Do you test for microbial contaminants? Do you test for potency? Do you have a terpenes profile test results? Do you test for residual solvents, heavy metals and mycotoxins? Do you declare the origin of where the hemp was grown? If they satisfy all that and then can provide like a URL the public can see, they get a badge. That's pretty much all it is.

Do you think the association with recreational cannabis is good or bad for CBD as it goes bigger?

MK: The stigma is falling away from cannabis rapidly, because there's now all these modalities that don't include combustion. Smoking is really the thing that had the stigma around it. With that going away and more vaping going on and more edibles and more ways to consume, I think this will just blend together and it won't be as big of a thing.

We've seen CBD as a hot dog topping, in a beard balm and in nail polish. Do you ever worry that it's turning into a joke?

MK: I think this is natural for any new product that is truly new that captured the public's attention. We kind of saw the same thing with blockchain. We saw software and companies coming out with their own blockchain coin and all these things that seemed totally unnecessary and superfluous. That will kind of drop away as the excitement fades and the game changers will remain. But I think that's a good sign that the public is excited about it.

Do you think a few primary uses will rise to the top?

MK: I think it's primarily going to be an ingredient that we look for in certain things, like how we look for menthol in Vicks Vapor Rub. We will start to look for CBD in teas and products as a critical active ingredient to experience relief. I think CBD if it's going to be associated with one word, it's going to be ‘relief’ and relief will mean different things to different people. I think anxiety and pain will be big, and for the boomers, probably arthritis. 


hempproductsconnect2.pngHemp Products Connect directory: Explore and compare responsible hemp and CBD brands and products backed by New Hope Network Standards.

Ex-FDA chief revisits efforts to modernize food labeling

nutrition-facts-label.png

At PLMA’s 2019 Private Label Trade Show, former Food & Drug Administration Commissioner Scott Gottlieb shed light on efforts to improve food labeling during his tenure at the agency.

Gottlieb, who led the FDA under President Trump from May 2017 until stepping down in March 2019, said he and his team aimed to modernize claims that could be permitted on food labels as well as make it easier for consumers to understand new and different ingredients in today’s foods. They also sought to update current standards of identity for foods.

“The efforts to try to modernize labeling included avenues to enable new claims on food labels that we thought would be easier for consumers to decipher and would encourage innovation among product manufacturers to develop potentially more healthful food,” Gottlieb said Monday in a keynote speech at the PLMA event in Chicago.

“One was the term ‘healthy’ on food labels. We undertook a regulatory process to try to update the definition of what it meant for food to be healthy. And that regulation is still in process,” he explained. “We also looked at whether we should be developing a regulation around the term ‘natural.’ That term has been used — and I think misused — a lot. Without a real standard definition from a regulatory standpoint governed by USDA, it means different things in different markets and on different products. We debated on whether we should step into that, and I think that debate is still ongoing.”

Scott_GottliebPLMA2019_1.jpg

The FDA under Gottlieb also started examining ways to simplify terminology used on ingredient lists to make food labels clearer and easier for consumers to comprehend. For example, he said, manufacturers could make ingredient names more understandable by listing “Vitamin B6” rather than its chemical name on a food label. He also cited a recent change with the salt alternative “potassium salt,” which FDA guidance updated in May allowed manufacturers to label the ingredient as “potassium chloride salt.”

“So we were looking at places where we could create opportunities to substitute a different term,” he said.

With standards of identity, or what needs to be in a food to meet a certain classification, Gottlieb said the FDA aimed to pare regulation that may have been overreaching and clarify regulation as product categories have evolved.

“We literally had a standard of identity for frozen cherry pie that mandated how many cherries needed to be in the pie,” he said. “So this became kind of a flashpoint in our efforts to deregulate in the food space and create a little bit more sensible approaches.”

Meanwhile, innovations in categories cheese, yogurt and milk—which has expanded into new items like rice, almond and oat milk—called for the agency to revisit certain standards of identity so consumers could better understand exactly what they’re purchasing. Plant-based meats also are presenting new challenges.

“To give you some examples of what we were looking at, as many of you know, bread, jam, juice, chocolate, etc., all have standards of identity,” Gottlieb said. “These standards serve an important purpose. They let consumers know that there are certain standards in terms of what's in a product. I think it was important that we take a fresh look at the existing standards in light of marketing trends, in light of nutritional science and in light of innovation in the marketplace and what product developers want to do.”

Confusing labels

Amid heightened consumer awareness of health and wellness, the FDA also targeted the inappropriate use of terms like non-GMO and gluten-free on food labels.

“We had a lot of concerns about things like non-GMO or gluten-free labeling on products that would never have gluten in them, like putting ‘gluten-free’ on a bottle of water. This actually may conflict with FDA guidance and regulation, if you put non-GMO labeling on something that couldn't possibly be made with GMOs or there are no competing products in the market that have GMOs in them,” explained Gottlieb. “The problem is those kinds of things are confusing to consumers and exacerbate misguided concerns around these kinds of ingredients. So we were concerned about this and skeptical, and I think the agency is going to continue to take that posture. As an aside, the sort of skepticism that's been created around GMO food is a valuable lesson as we think of some of the new innovations coming on the market.”

During his time at the helm of the FDA, Gottlieb also was charged with helping to slash drug prices and unfurl regulatory snags to speed approvals of new medicines. He also made significant achievements in improving in the food recall process and tracing sources of contamination and cracking down on opioid misuse and the use of tobacco and electronic cigarettes, especially among youths.

Gottlieb noted that this Wednesday, November 20, the Senate is scheduled to hold a confirmation hearing for Stephen Hahn, whom Trump nominated as FDA commissioner earlier this month to take over from acting commissioner Norman Sharpless.

“I think it’s important to get him confirmed and get determined leadership at that position,” Gottlieb said of Hahn. “Because as much as that agency really is led by the professional staff, trying to run policy through the administration, through the Office of Management and Budget, and through Capitol Hill to get resources to the agency is an inherently political business. So having a political leader of that agency is exceedingly important.”

Supermarket News logoThis piece originally appeared on Supermarket News, a New Hope Network sister website. Visit the site for more grocery trends and insights.

Michael Mooney, co-founder of SuperNutrition USA, passes away

MIchael-Mooney-obit.jpg

With sadness we report that Michael Mooney passed away in his home in Portland, Oregon, on November 9th, 2019.

In 1973, Michael and his biochemist father, Patrick Mooney, created a not-for-profit vitamin research co-op that led to the development and co-founding in 1977 of SuperNutrition and its state-of-the-art supplements. The company created the world’s first gluten-free multivitamins and the first science-based optimal potency multivitamins. Together Michael and Patrick were early champions for the supplement industry; they were at the forefront of political activism and helped pass the Dietary Supplement Health and Education Act (DSHEA) in 1994. SuperNutrition continued to be a pioneer in the nutrition supplement industry for decades until it was acquired by NOW Health Group in September 2019. 

Over his time in the industry, Michael became a leader in nutritional science. He devoted five years of service as the Director of Research and Education for Program for Wellness Restoration, a nonprofit HIV/AIDS educational organization that focuses on a more natural approach to HIV/AIDS wellbeing that targets patients' nutrition, physical activity and hormonal intervention.

Michael also served eight terms as the Political Committee Chairperson or Co-Chairperson of the NORCAL chapter of Natural Products Association; in 1992, he co-founded the San Francisco branch of Citizens For Health to help pass the Dietary Supplement Health and Education Act of 1994. Michael received the “Outstanding Health Freedom Activist Award” when the largest letter-writing campaign in history caused Congress to pass DSHEA.

Throughout his life, Michael worked tirelessly advocating for and researching the science of nutrition and age reversal. He brought his brilliance and passion to new frontiers, creating nutritional protocols that raised the standards of care for HIV, cancer cachexia and burn treatment. For these and other efforts to improve our understanding of holistic health, he earned recognition from esteemed colleagues and the gratitude of thousands of people whose lives he saved and helped regain health with his guidance.

Michael cofounded The Program for Wellness Restoration with Nelson Vergel; in 2000 they co-wrote the book "Built to Survive," a holistic health-oriented guide to living with HIV. 

In 2015 Michael received the Lifetime Achievement Award in the Hall of Legends at the Natural Products Expo given by the New Hope Network.

Michael is survived by his sisters, Kathy and Kim Mooney.  The family is planning to hold memorial services sometime early next year.  Notices will be forthcoming.

[email protected]: Packaging industry responds to PFAS | The rise of the wellness beverage

Getty Images Cuomo Unveils 5th Proposal Banning Single-use Styrofoam

The packaging industry takes on PFAS 'forever chemicals' in our food supply

In 2019 the issues surrounding the highly mobile per- and polyfluroalkyl chemicals (PFAS) in food packaging really started gaining momentum. As a result, states like Maine and Washington are already passing legislation to ban such products and the $16 billion compostable, environmentally friendly food packaging industry is working together to provide several viable alternatives. Read more at Civil Eats

Drink up, calm down

Functional beverage brands such as Recess and Kin are successfully capitalizing on anxious consumers' desire for an easy calming fix as well as the growing sober-curious movement. However, some herbalists argue that the add-ins common in these products cannot possibly have the advertised effect unless taken regularly and at much higher doses; there are also concerns over whether these products are just commodified wellness Band-Aids that do nothing to fix the far bigger societal problems that are at the root of many younger consumers' anxieties. Read more at Eater

Crowd Cow promised to bring craft meat to the masses. Some ranchers say it's been a bad deal

Startup Crowd Cow is facing criticism from some meat producers after it struggled to create a successful platform for "small family farmers and ranchers to deliver meat directly to the kitchens of eager eaters." While the company raised millions in venture capital, its founders knew little to nothing about the cattle business, leading to a series of financial losses and tarnished reputations on the parts of farmers and processors. Read more at New Food Economy

Your health data isn't as safe as you think

The laws that protect patients' health information aren't evolving as fast as health-focused technology from companies such as Apple and Facebook. These consumer-facing companies often aren't obligated to sign these agreements because the Health Insurance Portability and Accountability Act doesn't apply when personal information is shared voluntarily by the patient. Read more at The Wall Street Journal

Beyond Meat vs. Zhenmeat: The battle for China's meatless market

Chinese consumers are taking the plunge into realistic plant-based meat substitutes thanks in part to emerging local players such as Zhenmeat and Starfield. Zhenmeat in particular is looking to differentiate itself from U.S.-based alt meat company Beyond Meat by nailing the flavor profile behind pork. China's "free from meat" market has growin 33.5% since 2014 and was found to be worth $9.7 billion in 2018. Read more at Reuters

Supplement industry news and updates – November 2019

LeadPromo_sponsors_1200x400.jpg

[Video] The importance of nutrition science

While interpreting research accurately and conducting studies without bias continues to be a challenge, when done right, credible science helps take the supplement industry to the next level. Here, Inside the Bottle's industry pros break down the importance of nutrition science. 

Dieticians get on board with supplements …

for themselves and for their patients, according to a new survey from Trust Transparency Center (TTC). In the 2019 Registered Dietitian Insights Survey of 200 U.S.-based registered dietitian nutritionists, 66% of RDNs stated they recommend both food and supplements to their clients and 70% personally take supplements four times or more per week.

Get the latest on AHPA’s 2020 labeling guidance

The American Herbal Products Association has revised its free labeling guidance for herbal dietary supplements to cover updated nutrition labeling requirements for foods and dietary supplements, and it’s scheduled to take effect Jan. 1, 2020. Here’s what you need to know to be prepared for the year ahead.

Supplement raw material market reaches $6.3B

Raw materials, the foundation of the supplement industry, now represent $6.3 billion in annual sales. Nutrition Business Journal’s senior analyst digs into the numbers and explores trends and opportunities defining the future of raw materials.

How savvy are retailers about immunity supplements?

It’s critical that retailers stay informed about condition-specific options, especially during key times of the year. Natural Foods Merchandiser visited one store to test the staff’s knowledge on the immunity category and help others in the industry understand how to talk about the category.

Inside the Bottle unites companies from across the supplement supply chain to advocate for a transparent, collaborative supplement industry that supports consumer health empowerment.  

#InsidetheBottle